Enliven Therapeutics Q1 net loss $14.7M; cash $292.1M; dosed first patient in ELVN-002 Phase 1

Enliven Therapeutics, Inc.

2023-Q1 EPS reported -$0.80

Net loss of $14.7M for Q1 2023 vs $8.7M in Q1 2022; R&D expenses $11.9M, G&A $4.5M.
Cash and equivalents $292.1M as of March 31, 2023, expected to fund operations into early 2026.
Dosed first patient in Phase 1 trial of ELVN-002 for HER2-altered NSCLC and other solid tumors.
Enrollment progressing in Phase 1 trial of ELVN-001 for CML; initial safety/efficacy data expected in 2024.
Completed merger with Imara Inc. in February 2023; shares now trade as ELVN on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.